mecamylamine has been researched along with Child Development Disorders, Pervasive in 1 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Child Development Disorders, Pervasive: Severe distortions in the development of many basic psychological functions that are not normal for any stage in development. These distortions are manifested in sustained social impairment, speech abnormalities, and peculiar motor movements.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mecamylamine, because of its safety record in children with other disorders, was chosen for this first exploration." | 2.77 | Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. ( Aman, MG; Anand, R; Arnold, LE; Bates, B; Farmer, C; Hollway, J; Hurt, E; Li, X; Ramadan, Y; Thompson, S; Williams, C, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, LE | 1 |
| Aman, MG | 1 |
| Hollway, J | 1 |
| Hurt, E | 1 |
| Bates, B | 1 |
| Li, X | 1 |
| Farmer, C | 1 |
| Anand, R | 1 |
| Thompson, S | 1 |
| Ramadan, Y | 1 |
| Williams, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuronal Nicotinic Receptor Modulation in the Treatment of Autism: A Pilot Trial of Mecamylamine[NCT00773812] | Phase 1 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for mecamylamine and Child Development Disorders, Pervasive
| Article | Year |
|---|---|
Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders.
Topics: Child; Child Development Disorders, Pervasive; Child, Preschool; Constipation; Dose-Response Relatio | 2012 |